Two-Year Outcomes of Prostatic Artery Embolization for Symptomatic Benign Prostatic Hyperplasia: An International,...

Area of Science:

• Interventional Radiology
• Urology
• Men's Health

Background:

• Benign prostatic hyperplasia (BPH) is a common condition causing lower urinary tract symptoms (LUTS).
• Prostatic artery embolization (PAE) is an emerging minimally invasive treatment option for symptomatic BPH.
• Long-term clinical outcomes of PAE for BPH require further investigation.

Purpose of the Study:

• To evaluate the clinical outcomes of patients with symptomatic benign prostatic hyperplasia (BPH) 24 months after undergoing prostatic artery embolization (PAE).
• To assess the efficacy and safety of PAE in improving lower urinary tract symptoms (LUTS) and quality of life (QoL).

Main Methods:

• An international, multicenter, prospective trial involving males with BPH treated with PAE.
• Primary outcome: 12-month change in International Prostate Symptom Score (IPSS) for LUTS or catheter independence for acute urinary retention (AUR).
• Secondary outcomes: IPSS, QoL, Sexual Health Inventory for Men (SHIM) scores, technical success, and adverse events (AEs) at 3, 12, and 24 months.

Main Results:

• Significant improvements in IPSS and QoL were observed at 3, 12, and 24 months post-PAE for LUTS patients (p < 0.001).
• 65.8% of AUR patients achieved catheter independence within 3 months, maintaining it at 24 months.
• Mean SHIM scores remained stable; 11.5% experienced AEs, with 2.1% experiencing serious AEs.

Conclusions:

• Prostatic artery embolization (PAE) is a safe and effective treatment for symptomatic BPH and LUTS.
• PAE demonstrates sustained efficacy and a favorable safety profile at 24 months.
• PAE offers a viable alternative for managing BPH, including cases of AUR.